Analysts Offer Predictions for OPKO Health, Inc.’s FY2026 Earnings (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPKFree Report) – Stock analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for OPKO Health in a report issued on Tuesday, March 19th. Zacks Research analyst I. Bandyopadhyay anticipates that the biotechnology company will post earnings of ($0.09) per share for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.31) per share.

Several other equities analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Wednesday, February 28th. Barrington Research lowered their price objective on OPKO Health from $2.00 to $1.50 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Finally, StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st.

Get Our Latest Analysis on OPKO Health

OPKO Health Trading Up 2.3 %

Shares of OPK opened at $0.89 on Wednesday. OPKO Health has a 12-month low of $0.85 and a 12-month high of $2.24. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $620.32 million, a price-to-earnings ratio of -3.56 and a beta of 1.80. The stock’s 50-day moving average price is $0.98 and its 200 day moving average price is $1.30.

OPKO Health (NASDAQ:OPKGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $181.90 million for the quarter, compared to analyst estimates of $177.53 million. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.11) earnings per share.

Insiders Place Their Bets

In other news, Vice Chairman Elias A. Zerhouni acquired 550,300 shares of OPKO Health stock in a transaction on Friday, January 5th. The shares were purchased at an average price of $0.93 per share, with a total value of $511,779.00. Following the acquisition, the insider now owns 20,327,814 shares in the company, valued at $18,904,867.02. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Phillip Md Et Al Frost purchased 1,500,000 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were bought at an average price of $0.90 per share, with a total value of $1,350,000.00. Following the purchase, the chief executive officer now directly owns 203,456,694 shares in the company, valued at approximately $183,111,024.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman Elias A. Zerhouni purchased 550,300 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was bought at an average cost of $0.93 per share, for a total transaction of $511,779.00. Following the purchase, the insider now owns 20,327,814 shares in the company, valued at $18,904,867.02. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 8,993,015 shares of company stock valued at $8,479,069. 47.26% of the stock is currently owned by corporate insiders.

Institutional Trading of OPKO Health

A number of large investors have recently made changes to their positions in OPK. Envestnet Asset Management Inc. increased its position in shares of OPKO Health by 29.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 58,570 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 13,214 shares in the last quarter. Cetera Advisor Networks LLC increased its holdings in OPKO Health by 33.7% during the 1st quarter. Cetera Advisor Networks LLC now owns 15,156 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 3,820 shares in the last quarter. MetLife Investment Management LLC increased its holdings in OPKO Health by 70.6% during the 1st quarter. MetLife Investment Management LLC now owns 206,296 shares of the biotechnology company’s stock worth $710,000 after purchasing an additional 85,349 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in OPKO Health by 73.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company’s stock worth $24,717,000 after purchasing an additional 3,037,320 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its holdings in OPKO Health by 11.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 94,071 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 22.03% of the company’s stock.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

See Also

Earnings History and Estimates for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.